Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00406276|
Recruitment Status : Terminated (data analysis showed insufficient drug efficacy)
First Posted : December 4, 2006
Results First Posted : May 28, 2012
Last Update Posted : August 23, 2013
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Drug: RAD001 Drug: Docetaxel||Phase 1 Phase 2|
This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.
New agents and regimens are urgently needed for lung cancer treatment. With the development of novel agents and small molecules designed to curtail the aggressive aspects of this disease, some progress has been realized. However, much more effort and insight will be required for further real gains to be made. We propose that studying the mTOR axis, known to be abnormal in non-small cell lung cancer (NSCLC), and translating that knowledge into therapeutic adjustments can lead to meaningful advances in lung cancer treatment.
Approximately 58 patients will participate at Emory Winship Cancer Institute and Emory Crawford W. Long Hospital in Atlanta, Georgia.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer|
|Study Start Date :||November 2006|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||February 2013|
RAD001 in combination with Docetaxel.
RAD001 will be given at a dose of 5mg/day in combination with docetaxel
In combination with RAD001
- Number of Subjects Showing Partial Response and Stable Disease With the Combination of RAD001 and Docetaxel. [ Time Frame: 6 weeks ]
Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive disease (PD), taking as reference the smallest sum Longest diameter(LD) since treatment started.
- Time to Progression:Time Period (in Months) From Study Entry Until Disease Progression, Death, or Last Date of Contact. [ Time Frame: 6 months ]
Period from study entry until disease progression, death, or last date of contact.
Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406276
|United States, Georgia|
|Emory University Winship Cancer Institute|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Suresh Ramalingam, MD||Emory University Winship Cancer Institute|